Zaina Al-Mohtaseb, MD
Ophthalmology · Houston, TXNPI 1659506822
Payments from drug & device makers
Across 759 payments — averaging $1428.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$404K
- Tarsus Pharmaceuticals, Inc.$168K
- Alcon$124K
- Alcon Research LLC$88K
- Johnson & Johnson Surgical Vision, Inc.$82K
- Bausch & Lomb Americas Inc.$46K
- plus $172K from 23 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 121 | $403,691 |
| Tarsus Pharmaceuticals, Inc. | 91 | $167,657 |
| Alcon | 146 | $123,787 |
| Alcon Research LLC | 77 | $88,044 |
| Johnson & Johnson Surgical Vision, Inc. | 49 | $81,792 |
| Bausch & Lomb Americas Inc. | 52 | $46,468 |
| Carl Zeiss Meditec, Inc. | 37 | $42,839 |
| AbbVie(2 entities) | 43 | $37,206 |
| Beaver-visitec International, Inc. | 13 | $24,000 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 20 | $19,009 |
| Novartis | 17 | $13,199 |
| Ocular Therapeutix, Inc. | 15 | $9,731 |
| Dompe US, Inc. | 12 | $9,463 |
| Rxsight Inc | 4 | $5,073 |
| Shire North American Group Inc | 6 | $4,348 |
| Harrow Eye, LLC | 7 | $1,881 |
| Thea Pharma Inc. | 2 | $1,473 |
| Eyevance Pharmaceuticals LLC | 3 | $1,341 |
| Kala Pharmaceuticals, Inc. | 3 | $1,038 |
| Sun Pharmaceutical Industries Inc. | 14 | $660 |
| Carl Zeiss Meditec USA, Inc. | 8 | $602 |
| Oyster Point Pharma, Inc. | 3 | $149 |
| Biotissue Holdings Inc. | 4 | $98 |
| Omeros Corporation | 2 | $78 |
| Carl Zeiss Meditec Production LLC | 1 | $69 |
| Amgen | 2 | $59 |
| Sight Sciences, Inc. | 3 | $59 |
| Astellas Pharma US Inc | 2 | $46 |
| Tearlab Corp | 2 | $31 |
How this compares
$1,083,891 in reported general payments places this provider in the 95th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other ophthalmology in Houston
- David BrownHouston$51.7M
- John MichelettiHouston$3.3M
- Michael CaplanHouston$1.4M
- Shaheen KavoussiHouston$1.3M
- Kevin JongHouston$1.2M
- Stephen SladeHouston$1.2M
- Rosa TangHouston$1.1M
- Fiaz ZamanHouston$1M
- Stephen PflugfelderHouston$788K
- Christina WengHouston$722K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.